## 1. Signatures

I have read the amendment and agree that the trial will be conducted according to the procedures described.

| Function | Name | Date | Signature |
|---|---|---|---|
| Principal Investigator | Prof Robert Sauerwein | 24/6/05 | |
| Investigator | Dr Meta Roestenberg | 24/06/05 | |
| E.M.V.I. Project manager | Dr Hildur E. Blythman | 24.06.05 | |
| E.M.V.I. Director of Clinical and Regulatory Affairs | Dr Odile Leroy | 22/06/05 | |

## 2. Justification of the amendment

The paragraphs modified by this amendment are described below. Other paragraphs remain unchanged

Page 35 and 36

**7.2.2. Cellular Immune response**:

**2. Parameters to be measured, Method and Timing of Measurement**

Cytokine production will be assayed by ELISPOT for the cytokines IL-4 and IFNγ

*Change to:*

Cytokine production will be assayed by ELISPOT for the cytokines IL-5 and IFNγ

Justification for the change:

- The IL-4 production of Polymorphic Blood Mononuclear Cells (PBMC's) measured in the ELISPOT is low as compared to the IL-5 production. Therefore, due to the low numbers of spots, the read-out will be less reproducible and the intra-assay variability will be higher as compared to IL-5.
- ELISPOT results from this study can easily be compared with the IFNγ/IL-5 data published by researchers of GSK[1], [2], one of the co-investigators in this study.


[1] Walsh DS, Pichyangkul S, Gettayacamin M, et al. Safety and immunogenicity of rts,s+trap malaria vaccine, formulated in the as02a adjuvant system, in infant rhesus monkeys. Am.J.Trop.Med.Hyg. 2004;70(5):499-509.

[2] Pichyangkul S, Gettayacamin M, Miller RS, et al. Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum. Vaccine 2004;22(29-30):3831-40.

## 3. Appendixes

1. Amendment List

| Amendment number | Date | Protocol file name | Version | EC submission | |
|---|---|---|---|---|---|
| | | | | Yes/ No | date |
| 1 | 03/03/05 | PAMA1 050303 | Final_1 | No | |
| 2 | 16/05/05 | PAMA1 050516 | Final_2 | | |

2. Amended protocol